Lupus treatment centers on controlling inflammation, preventing flares, and protecting organs from long-term damage. There is no cure, but most people with systemic lupus erythematosus (SLE) can reach a state of low disease activity with the right combination of medications, lifestyle adjustments, and ongoing monitoring. The specific plan depends on which organs are affected and how severe the disease is, but nearly every lupus patient starts with the same foundational medication.
Hydroxychloroquine: The Cornerstone Drug
Hydroxychloroquine is prescribed to virtually everyone diagnosed with lupus, regardless of severity. It reduces disease activity in mild to moderate cases, prevents flares, lowers the need for steroids over time, and has a measurable impact on long-term survival and organ damage. Most rheumatologists consider it a lifelong medication.
The standard dose is based on body weight, capped at 5 mg per kilogram per day. For someone over about 175 pounds, that typically means 400 mg daily. The dosing cap exists not because higher amounts work better, but because they raise the risk of retinal toxicity, a rare but serious side effect involving the eyes. You’ll need regular eye exams (usually annual after the first five years) to catch any changes early.
Hydroxychloroquine takes weeks to months to reach full effect, so it’s not a rescue drug for acute symptoms. Its value is cumulative: the longer you stay on it, the more protection it offers against damage accrual and disease progression.
How Flares Are Managed
Even with good baseline control, lupus flares happen. The approach to treating them depends on severity, and the central goal in modern rheumatology is to use the lowest effective dose of steroids for the shortest possible time. Long-term steroid exposure causes its own damage, including bone loss, weight gain, high blood sugar, and increased infection risk.
For mild flares, your doctor may temporarily bump your prednisone dose to around 5 to 7.5 mg per day, then taper back down within two weeks. Moderate flares often call for a short burst of higher-dose intravenous steroids over three days, followed by oral prednisone starting at 5 to 20 mg daily with a taper over two to four weeks. Severe flares involving major organs follow a similar pattern but with higher initial doses, sometimes starting at 20 to 30 mg daily after the intravenous pulse, then stepping down every two weeks until reaching 5 mg or less.
The target for ongoing maintenance is a prednisone dose no higher than 5 mg per day. Staying at or below this threshold is one of the criteria doctors use to define “low disease activity,” a treatment milestone that signals your lupus is well controlled with tolerable medications.
Immunosuppressive Medications
When hydroxychloroquine alone isn’t enough to keep lupus in check, or when you can’t taper steroids low enough, immunosuppressive drugs become part of the plan. The two most common options for skin and joint involvement are mycophenolate and methotrexate.
Both work by dialing down the overactive immune response driving lupus. In studies of lupus skin disease, methotrexate produced a response in about 72% of patients with one common subtype (subacute cutaneous lupus) and 46% with another (discoid lupus). Mycophenolate showed similar results for the first subtype (71%) and was notably better for discoid lupus, with a 70% response rate. The overall average response rate across studies was about 65%.
The most common reason people stop either drug is nausea and diarrhea. Methotrexate can also elevate liver enzymes, which requires periodic blood work. Mycophenolate had a higher discontinuation rate due to side effects in some patient groups (up to 46% in one subtype), so your doctor will monitor you closely in the first few months and may switch medications if you’re struggling with tolerability.
When Lupus Affects the Kidneys
Lupus nephritis, where the immune system attacks kidney tissue, requires more aggressive treatment. It’s one of the most serious complications of lupus and has its own treatment pathway. Patient and kidney survival rates have improved significantly since the 1970s thanks to combined immunosuppressive regimens.
Treatment unfolds in two phases. The induction phase aims to stop active kidney inflammation quickly, using steroids alongside immunosuppressive drugs like mycophenolate or cyclophosphamide. Once the inflammation is controlled, you shift to a maintenance phase designed to keep it from coming back, typically with lower doses of the same immunosuppressive plus hydroxychloroquine.
A newer option approved in 2021 specifically for lupus nephritis is voclosporin, a calcineurin inhibitor taken twice daily by mouth on an empty stomach. It’s approved for biopsy-confirmed cases and is used alongside other immunosuppressive therapy, not as a standalone treatment. Because it can affect kidney function itself, your doctor will track your kidney filtration rate closely and adjust the dose if it drops. Voclosporin isn’t appropriate for everyone; it’s contraindicated when kidney function is already severely reduced.
If you have lupus nephritis with significant protein in your urine or high blood pressure, your treatment plan will also include a blood pressure medication from the ACE inhibitor or ARB class, with a target below 130/80 mm Hg.
Biologic Therapies
For people with moderate to severe lupus that doesn’t respond well enough to standard treatment, two biologic drugs are now FDA-approved.
Belimumab works by blocking a protein that helps certain immune cells survive, reducing the autoimmune attack. It’s available as both an intravenous infusion and a subcutaneous injection and was the first biologic approved specifically for lupus.
Anifrolumab targets a different part of the immune system: the interferon pathway, which is abnormally active in many lupus patients. It’s given as an intravenous infusion over 30 minutes every four weeks. It’s approved for moderate to severe SLE in adults already on standard therapy, but it hasn’t been studied in patients with severe active kidney disease or central nervous system lupus, so it’s not recommended in those situations.
Both biologics are add-on treatments, meaning they’re layered on top of hydroxychloroquine and other medications rather than replacing them.
Sun Protection and Lifestyle
Ultraviolet light is one of the most reliable triggers for lupus flares, particularly skin flares. What makes it tricky is that there’s often a delay between sun exposure and the flare itself, sometimes days or weeks, which can make it hard to connect cause and effect.
Daily broad-spectrum sunscreen is essential, not just on beach days. Research on lupus patients found that only about half of those who used sunscreen reapplied it during the day, and just a third applied it the recommended 30 minutes before going outside. These habits matter. Providers who treat lupus emphasize that consistent daily application, reapplication every couple of hours when outdoors, and combining sunscreen with protective clothing and shade avoidance during peak hours makes a meaningful difference in flare frequency.
Cardiovascular Risk
Lupus significantly increases your risk of heart disease and stroke, driven by chronic inflammation and certain disease-related factors on top of the usual risks like high cholesterol, smoking, and inactivity. European guidelines recommend that every lupus patient receive a thorough assessment of both traditional cardiovascular risk factors (blood pressure, cholesterol, blood sugar, smoking status) and disease-specific risks.
Blood pressure targets are tighter for lupus patients than for the general population. The recommended goal is below 130/80 mm Hg. For cholesterol, treatment follows the same guidelines as the general population; a lupus diagnosis alone isn’t a reason to start cholesterol-lowering medication, but your overall risk profile might be.
Omega-3 Supplements
Omega-3 fatty acid supplements have shown modest but real benefits for lupus disease activity. A systematic review of ten trials found that eight showed improvement in the omega-3 group, with statistically significant reductions in disease activity scores at both 12 and 24 weeks. The supplements also reduced a urinary marker of inflammation and oxidative stress.
The benefits had limits, though. Omega-3s didn’t improve kidney-specific measures like creatinine or urine protein, and they didn’t change key immune markers like complement levels or anti-DNA antibodies. They appear to help with overall symptom burden and inflammation rather than targeting any specific organ. Side effects were minimal across trials, making them a reasonable addition to standard treatment for most people.
What “Well-Controlled” Lupus Looks Like
The formal treatment target most rheumatologists aim for is called the Lupus Low Disease Activity State. You’ve reached it when your disease activity score is 4 or below on the standard scale, with no activity in major organ systems (kidneys, brain, heart, lungs, blood vessels). You should have no new disease activity compared to your last visit, your doctor’s overall assessment of your disease is minimal, your daily steroid dose is 7.5 mg or less, and you’re tolerating your maintenance medications well.
Reaching this state doesn’t mean you’re cured or that treatment stops. It means your disease is in a stable, manageable range where ongoing damage is unlikely to accumulate. For many people, staying in low disease activity over time is a realistic and meaningful goal that translates to better quality of life and fewer long-term complications.